Metsera (NASDAQ:MTSR) Shares Up 4.7% – Should You Buy?

Metsera, Inc. (NASDAQ:MTSR)’s stock price rose 4.7% on Monday . The company traded as high as $20.71 and last traded at $20.49. Approximately 137,510 shares were traded during trading, a decline of 83% from the average daily volume of 830,136 shares. The stock had previously closed at $19.57.

Wall Street Analyst Weigh In

Several brokerages recently commented on MTSR. Bank of America began coverage on shares of Metsera in a research note on Tuesday, February 25th. They issued a “buy” rating and a $38.00 price objective for the company. Evercore ISI initiated coverage on Metsera in a report on Tuesday, February 25th. They issued an “outperform” rating on the stock. Guggenheim started coverage on Metsera in a research report on Tuesday, February 25th. They set a “buy” rating and a $56.00 target price on the stock. Finally, Cantor Fitzgerald initiated coverage on Metsera in a research report on Tuesday, February 25th. They set an “overweight” rating for the company.

Metsera Stock Up 11.1 %

The company has a fifty day simple moving average of $24.41.

Metsera (NASDAQ:MTSR) last released its earnings results on Wednesday, March 26th. The company reported ($3.52) earnings per share (EPS) for the quarter.

Metsera Company Profile

Metsera, Inc is a clinical stage biopharmaceutical company, which engages in the development of a next-generation injectable and oral nutrient stimulated hormone, or NuSH, analog peptides to treat obesity, overweight and related conditions. Its product pipeline includes MET-097i, MET-233, and MET-224o.